International Business Machines Corporation (NYSE:IBM) [Trend Analysis] retains strong position in active trade, as shares scoring 0.39% to $159.29 in a active trade session, while looking at the shares volume, about 2.25 Million shares have changed hands in this session. Resilient, an IBM Firm (NYSE: IBM) and Ponemon Institute unveiled the results of the yearly Cyber Resilient Organization study, which found that only 32 percent of IT and security professionals say their organization has a high level of Cyber Resilience down slightly from 35 percent in 2015.
The 2016 study also found that 66 percent of respondents say their organization is not prepared to recover from cyberattacks. For the second straight year, the study showed that challenges with incident response (IR) are hindering Cyber Resilience. Seventy-five percent of respondents admit they do not have a formal cyber security incident response plan (CSIRP) that is applied consistently across the organization.
Of those with a CSIRP in place, 52 percent have either not reviewed or updated the plan since it was put in place, or have no set plan for doing so. Additionally, 41 percent say the time to resolve a cyber incident has surged in the past 12 months as compared to only 31 percent who say it has reduced. The firm has institutional ownership of 60.30%, while insider ownership included 0.05%. IBM attains analyst recommendation of 2.80 with week’s performance of 2.89%. Investors looking additional ahead will note that the Price to next year’s EPS is 3.48%.
Medovex Corp. (NASDAQ:MDVX) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -1.35% to 1.46 with about 43108 shares have changed hands in this session. Medovex Corp. (NASDAQ:MDVX) reported that the Firm has designated Jill Schweiger as its new Senior Vice President of Regulatory, Clinical and Quality. Schweiger is a highly qualified and completed leader with a highly demonstrable track record of success in the areas of clinical studies and regulatory affairs. She has before served as a Vice President and Director in at least six early stage medical device companies, as well as multinational med tech organizations such as Baxter Healthcare Corporation and Eli Lilly & Firm.
“I’m really thrilled to join the Medovex team as it continues to move toward the anticipated European launch of its disruptive DenerveX™ System. I am confident that my background in developing and completing European and US clinical feasibility studies, combined with having before achieved CE Marking for other companies, has prepared me well for my new role at Medovex”, stated Schweiger. The stock is going forward its fifty-two week low with 71.76% and lagging behind from its 52-week high price with -41.13%.
Same, the positive performance for the quarter recorded as 12.31% and for the year was 8.96%, while the YTD performance remained at 32.73%. MDVX has Average True Range for 14 days of 0.14.